Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.64 |
| ▸ | MTOR | P42345 | 13/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.64 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.48 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429333 | 1.00 | PIK3CA (0.64) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL4317983 | 0.94 | PIK3CA (0.55) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL1429091 | 0.94 | PIK3CA (0.55) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL4320279 | 0.91 | PIK3CA (0.56) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL1428791 | 0.91 | PIK3CA (0.56) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL4316045 | 0.87 | PIK3CA (0.62) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL1428771 | 0.87 | PIK3CA (0.62) | PIK3CAMTORPIK3CGABCC2INPPL1 | |
| SCHEMBL4318834 | 0.86 | PIK3CA (0.66) | PIK3CAMTORPIK3CG | |
| SCHEMBL1428885 | 0.86 | PIK3CA (0.66) | PIK3CAMTORPIK3CG | |
| SCHEMBL1433239 | 0.86 | PIK3CA (0.51) | PIK3CAMTORPIK3CGABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | claimed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | PIK3CA 4/4885MTOR 1/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.